



(51) International Patent Classification:

C07D 401/14 (2006.01) A61K 31/495 (2006.01)

A61P 35/00 (2006.01) A61K 31/4709 (2006.01)

(21) International Application Number:

PCT/IB2020/050009

(22) International Filing Date:

02 January 2020 (02.01.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/787,965 03 January 2019 (03.01.2019) US

62/858,819 07 June 2019 (07.06.2019) US

62/947,720 13 December 2019 (13.12.2019) US

(71) Applicant: ARRAY BIOPHARMA INC. [US/US]; 3200 Walnut Street, Boulder, CO 80301 (US).

(72) Inventors: COOK, Adam; c/o Array Biopharma Inc., 3200 Walnut Street, Boulder, CO 80301 (US). HINKLIN, Ronald Jay; c/o Array Biopharma Inc., 3200 Walnut Street, Boulder, CO 80301 (US). MCNULTY, Oren T.; c/o Array Biopharma Inc., 3200 Walnut Street, Boulder, CO 80301 (US).

(74) Agent: ZIELINSKI, Bryan C. et al.; Pfizer Inc., 235 East 42nd Street, MS 235/9/S20, New York, NY 10017 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with amended claims (Art. 19(1))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: QUINOLINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES



(I)

(57) Abstract: Provided herein are compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X^1 , X^2 , X^3 , R^1 , R^2 , R^3 , R^4 , R^5 , R^6 and R^7 are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.